MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday

MaxCyte (NASDAQ:MXCT – Get Rating) is set to announce its earnings results after the market closes on Wednesday, August 10th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

MaxCyte (NASDAQ:MXCT – Get Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. MaxCyte had a negative return on equity of 7.39% and a negative net margin of 41.15%. The company had revenue of $11.59 million for the quarter, compared to analyst estimates of $11.00 million. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Stock Performance

Shares of MXCT opened at $5.66 on Wednesday. The firm has a 50 day simple moving average of $4.67. The firm has a market capitalization of $575.23 million and a price-to-earnings ratio of -33.29. MaxCyte has a 12 month low of $3.36 and a 12 month high of $17.26.

Insider Transactions at MaxCyte

In other news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of MaxCyte stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $4.30, for a total value of $13,912,856.40. Following the sale, the insider now directly owns 10,735,786 shares of the company’s stock, valued at $46,163,879.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.11% of the company’s stock.

Institutional Trading of MaxCyte

Institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in MaxCyte by 317.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,003,738 shares of the company’s stock worth $7,016,000 after buying an additional 763,344 shares in the last quarter. State Street Corp lifted its position in MaxCyte by 19.2% during the first quarter. State Street Corp now owns 1,562,760 shares of the company’s stock worth $10,924,000 after buying an additional 252,201 shares in the last quarter. BlackRock Inc. lifted its position in MaxCyte by 4.4% during the first quarter. BlackRock Inc. now owns 5,443,837 shares of the company’s stock worth $38,052,000 after buying an additional 229,373 shares in the last quarter. Vanguard Group Inc. lifted its position in MaxCyte by 4.0% during the first quarter. Vanguard Group Inc. now owns 3,284,596 shares of the company’s stock worth $22,958,000 after buying an additional 126,906 shares in the last quarter. Finally, First Light Asset Management LLC lifted its position in MaxCyte by 7.2% during the first quarter. First Light Asset Management LLC now owns 1,321,406 shares of the company’s stock worth $9,237,000 after buying an additional 89,129 shares in the last quarter. 65.86% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

(Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.